A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Novartis
Novartis
Bristol-Myers Squibb
Novartis
Novartis
Novartis
Pfizer
M.D. Anderson Cancer Center
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Norwegian University of Science and Technology
Pfizer
M.D. Anderson Cancer Center
Novartis
Novartis
Novartis
Il-Yang Pharm. Co., Ltd.
M.D. Anderson Cancer Center
University of Bologna